Universal Beteiligungs und Servicegesellschaft mbH Buys 33,329 Shares of Exelixis, Inc. $EXEL

Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 6.7% during the 4th quarter, Holdings Channel reports. The fund owned 530,120 shares of the biotechnology company’s stock after purchasing an additional 33,329 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Exelixis were worth $23,246,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Evergreen Capital Management LLC boosted its position in Exelixis by 44.2% during the 4th quarter. Evergreen Capital Management LLC now owns 7,858 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 2,408 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Exelixis by 29.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,344 shares of the biotechnology company’s stock valued at $4,179,000 after acquiring an additional 21,688 shares in the last quarter. Krilogy Financial LLC boosted its position in Exelixis by 50.3% during the 4th quarter. Krilogy Financial LLC now owns 30,902 shares of the biotechnology company’s stock valued at $1,348,000 after acquiring an additional 10,338 shares in the last quarter. Earned Wealth Advisors LLC boosted its position in Exelixis by 33.4% during the 4th quarter. Earned Wealth Advisors LLC now owns 8,277 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 2,072 shares in the last quarter. Finally, Merit Financial Group LLC boosted its position in Exelixis by 25.4% during the 4th quarter. Merit Financial Group LLC now owns 86,956 shares of the biotechnology company’s stock valued at $3,811,000 after acquiring an additional 17,615 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other news, EVP Dana Aftab sold 47,918 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total value of $2,132,351.00. Following the completion of the sale, the executive vice president owned 616,106 shares of the company’s stock, valued at $27,416,717. This trade represents a 7.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jack L. Wyszomierski sold 99,574 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $4,382,251.74. Following the completion of the sale, the director directly owned 279,942 shares of the company’s stock, valued at $12,320,247.42. The trade was a 26.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 362,849 shares of company stock worth $15,917,463. 2.82% of the stock is currently owned by corporate insiders.

Exelixis Price Performance

Exelixis stock opened at $44.94 on Friday. The stock has a market capitalization of $11.42 billion, a price-to-earnings ratio of 16.22, a PEG ratio of 1.03 and a beta of 0.42. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $49.62. The business has a fifty day moving average price of $43.26 and a 200-day moving average price of $42.61.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.55 EPS. On average, equities research analysts anticipate that Exelixis, Inc. will post 3.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on EXEL. Truist Financial raised Exelixis to a “strong-buy” rating in a research report on Wednesday, March 25th. Royal Bank Of Canada dropped their target price on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research report on Monday, March 2nd. Stifel Nicolaus increased their target price on Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. Finally, HC Wainwright increased their target price on Exelixis from $52.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Exelixis presently has an average rating of “Hold” and a consensus target price of $47.00.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.